Clinical Proteomic Research for the Brain
| Status: | Recruiting |
|---|---|
| Conditions: | Peripheral Vascular Disease, Cardiology, Hospital, Neurology |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology, Other |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/2/2016 |
| Start Date: | July 2005 |
| End Date: | July 2016 |
| Contact: | MingMing Ning, M.D. (PI) |
| Email: | CPRBrain@mgh.harvard.edu |
| Phone: | 617-726-8459 |
Clinical Proteomic Research on the Brain
The study of plasma and urine proteomic profiles in patients with ischemic brain injury is
important to better understanding of the mechanisms by which thrombolytic agents or other
therapy affects clinical outcomes. The purpose of this study is to study the proteomic
profile of patients with ischemic brain injury and compare it to control subjects without
ischemic brain injury, subjects with other chronic neurologic diseases or systemic vascular
diseases, and pre- and post- therapy which may be associated with, or predictive of,
therapeutic outcome.
The investigators hypothesize that there is a unique set of proteins expressed in serum and
urine in patients with ischemic brain injury that may provide a more complete understanding
of ischemic brain injury pathophysiology.
Ultimately, this study may provide information of direct relevance to the medical care of a
large proportion of patients with ischemic brain injury and other neurologic diseases in the
future. And proteomic proteomic profile may provide important information about the roles of
specific biomarkers. Perhaps the prevention of ischemic injury related complications.
important to better understanding of the mechanisms by which thrombolytic agents or other
therapy affects clinical outcomes. The purpose of this study is to study the proteomic
profile of patients with ischemic brain injury and compare it to control subjects without
ischemic brain injury, subjects with other chronic neurologic diseases or systemic vascular
diseases, and pre- and post- therapy which may be associated with, or predictive of,
therapeutic outcome.
The investigators hypothesize that there is a unique set of proteins expressed in serum and
urine in patients with ischemic brain injury that may provide a more complete understanding
of ischemic brain injury pathophysiology.
Ultimately, this study may provide information of direct relevance to the medical care of a
large proportion of patients with ischemic brain injury and other neurologic diseases in the
future. And proteomic proteomic profile may provide important information about the roles of
specific biomarkers. Perhaps the prevention of ischemic injury related complications.
Case Inclusion and Exclusion Criteria:
Inclusion Criteria:
1. Ischemic brain injury within 12 hours of symptom onset;
2. Including primary ischemic brain injury from embolism or arterial occlusion or
secondary due to increased ICP after trauma, subarachnoid hemorrhage.
Exclusion Criteria:
1. Patients who are hemodynamically unstable for venipunctures;
2. Anemic patients (hemoglobin < 11);
3. Children;
4. Pregnant women.
Controls Inclusion and Exclusion Criteria:
Inclusion Criteria:
1. Healthy adults without any neurologic or systemic disease;
2. Inpatient or outpatient adults with a chronic stroke (greater than 3 months) or
chronic neurologic disease such as neurodegenerative disease, movement disorder,
demyelinating disease;
3. Inpatient or outpatient adults with systemic vascular disease.
Exclusion Criteria:
1. Patients who are hemodynamically unstable for venipunctures;
2. Anemic patients (hemoglobin < 11);
3. Children;
4. Pregnant women.
We found this trial at
1
site
Click here to add this to my saved trials
